CSF biomarkers in primary CNS lymphoma.
Rev Neurol (Paris)
; 179(3): 141-149, 2023 Mar.
Article
en En
| MEDLINE
| ID: mdl-36336490
ABSTRACT
PCNSL is a non-Hodgkin lymphoma (NHL) affecting brain, spinal cord, eyes and leptomeninges. In the past two decades, its prognosis significantly improved due to therapeutic advances but it remains a highly aggressive tumor and early diagnosis is necessary for optimal management. Diagnosis relies on the identification of lymphoma cells in brain tissue obtained by stereotactic biopsy. Alternatively, lymphoma cells may be found in CSF through lumbar puncture (LP) or by a vitrectomy. For several reasons, the diagnosis of PCNSL may be challenging. Misleading radiological presentations are frequent. Dramatic response to steroids may bias histological analysis and deep brain location or frail health status can contraindicate brain biopsy. In the follow-up of patients who have been previously treated, differential diagnosis between tumor relapse and post-treatment may be also difficult. Therefore, the development of complementary reliable diagnostic tools is needed. This review will summarize several diagnostic or prognostic CSF biomarkers which have been proposed in PCNSL, their interests and limits.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Linfoma no Hodgkin
/
Neoplasias del Sistema Nervioso Central
Tipo de estudio:
Screening_studies
Aspecto:
Patient_preference
Límite:
Humans
Idioma:
En
Revista:
Rev Neurol (Paris)
Año:
2023
Tipo del documento:
Article
Pais de publicación:
FR
/
FRANCE
/
FRANCIA
/
FRANÇA